Navigation Links
Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
Date:4/20/2009

Renowned Physicians Join World Class Group of Advisors

SAN DIEGO, April 20 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the expansion of its Clinical Advisory Board, naming Donald H. Batts, MD, FACP, FIDSA, and G. Ralph Corey, MD, as the sixth and seventh members of the group of anti-infective thought leaders. Dr. Batts is a Professor of Medicine at Michigan State University and the Chief of Infectious Diseases at its Kalamazoo Campus. Dr. Corey is the Gary Hock Distinguished Professor of Global Health and the Director of the Hubert/Yeargan Center for Global Health and Director of Infectious Disease Research at the Duke Clinical Research Institute.

"Don and Ralph bring years of academic and industry experience to the Advisory Board that will benefit us as we advance torezolid into Phase 3 development," said Philippe Prokocimer, MD, Chief Medical Officer of Trius. "Collectively, their clinical development of anti-infectives has contributed to the approval of several important new drugs."

"Torezolid is one of the most compelling antibacterial drugs in the clinic so I look forward to advising Trius on its continued development," said Dr. Batts, who was lead investigator at the Upjohn Company for the development of linezolid, the sole marketed antibiotic in the oxazolidinone class.

"I look forward to working closely with Dr. Prokocimer and the rest of the Trius team to help develop the clinical and regulatory strategy for torezolid as it moves into Phase 3 testing," said Dr. Corey.

"The guidance that these distinguished clinicians provide will be critical not only for torezolid as it transitions into Phase 3 testing, but also for our preclinical programs as we advance them toward Phase 1 testing," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Our goal is to provide patients and physicians best-in-class therapeutic options to address the growing unmet need for safe and effective treatments for drug resistant bacterial infections in the hospital and in the community."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has licensed worldwide rights outside of Korea to torezolid from Dong-A Pharmaceuticals. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Awarded $28 Million Contract to Develop Novel Antibiotics
2. Trius Appoints Paul Truex to Board of Directors
3. Ventus Medical Appoints John McCutcheon as President and CEO
4. Sinobiopharma, Inc. Appoints New Director of Marketing
5. Yongye Biotechnology Appoints New Chief Financial Officer
6. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
7. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
8. BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer
9. MacroGenics Appoints New Vice President of Business Development
10. DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors
11. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition of the ... offering. The report forecasts the ... at a CAGR of 12.28% during the period 2016-2020. ... analysis with inputs from industry experts. The report covers the market ... also includes a discussion of the key vendors operating in this ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):